Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research into the early detection of ovarian cancer by the Ahmed group, receives a boost thanks to a gift of £43,000 from the Dianne Oxberry Trust.

© Dr Siobhan Ferguson & Ian Hindle (Dianne Oxberry Trust), Prof Ahmed Ahmed, Abdulkhaliq Alsaadi & Mara Artibani (Weatherall Institute of Molecular Medicine, NDWRH, Oxford University)

Research into the early detection of ovarian cancer will receive a boost, thanks to a gift of £43,000 from the Dianne Oxberry Trust. The donation will support doctoral candidate Abdulkhaliq Alsaadi in this research by covering the stipend and other costs associated with his final year of study, including research consumables.

More than 250,000 women around the world are diagnosed with ovarian cancer every year, with almost half dying from the disease. This makes ovarian cancer the most common cause of death from a gynaecological malignancy. Late diagnosis a key contributing factor.

At Oxford, a concerted effort is being made to better understand the origins of the disease. Led by Professor Ahmed Ahmed, Professor of Gynaecological Oncology in the Nuffield Department of Women’s and Reproductive Health, researchers are utilising cutting-edge methodologies to classify the cells in the fallopian tube – thought to be the organ from which most ovarian cancers develop. It is hoped that this will lead to the discovery of new biomarkers that could be used for pre-cancer screening.

Working under Professor Ahmed’s supervision, Abdulkhaliq is developing a system for growing fallopian tub­e organoids (mini-fallopian tubes) in the lab. These organoids can be used to investigate the different cell types within fallopian tubes, and model how ovarian cancer starts. The Dianne Oxberry Trust’s generosity will enable Abdulkhaliq to continue this important work for a further year. 

Professor Ahmed says: ‘This very generous donation from the Dianne Oxberry Trust will support our endeavours to better understand how ovarian cancer begins. Early detection is crucial to surviving this terrible disease, and this funding from the Dianne Oxberry Trust gets us one step closer to reaching that goal.’

The Dianne Oxberry Trust was set up in the memory of BBC presenter Dianne Oxberry, who died from ovarian cancer in January 2019, at the age of 51. Established by her husband Ian Hindle, the trust supports those affected by ovarian cancer through the provision of grants, information and advice.

‘The work Professor Ahmed and his team are doing is incredible,’ says Ian. ‘Hopefully with our donation we are going to make a difference.’

Dr Siobhan Ferguson, Trustee of the Dianne Oxberry Trust, adds: ‘Knowing what we know about what happened to Dianne, how short her journey was, the emphasis on early diagnosis is so important. You really get a sense that the team are breaking ground and that they will perhaps, within our lifetime, be able to spot women much earlier in the disease process.’

 

 

Latest news

Researchers identify genetic cause of endometriosis and potential drug target

Endometriosis is a painful, chronic condition in which tissue from the uterus inappropriately grows outside the uterus.

Success with the Pfizer Maternal C-19 Vaccine Trial

Congratulations to Prof. Manu Vatish and the OSPREA-Gynae team on recruiting their first participant to the Pfizer maternal C-19 vaccine trial on 22nd July.

First woman in UK receives dose of therapeutic HPV vaccine

NDWRH and Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of vaccines for the treatment and prevention of infectious diseases and cancer, see the first woman in the UK receive the first dose of a novel therapeutic HPV vaccine for the HPV001 clinical trial in Oxford.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Similar stories

First woman in UK receives dose of therapeutic HPV vaccine

NDWRH and Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of vaccines for the treatment and prevention of infectious diseases and cancer, see the first woman in the UK receive the first dose of a novel therapeutic HPV vaccine for the HPV001 clinical trial in Oxford.

Singula Bio provides new hope for cancer with diverse, individualised therapies

The Oxford spinout will draw on a multi-discipline approach for therapies which work with a patient to eliminate cancer.

MitOX 2017 - 1st December

The Nuffield Department of Obstetrics & Gynaecology invites you to MitOX 2017 - an annual meeting with talks on mitochondrial genetics, physiology, neurosciences and cancer.

Cancer hijacks natural cell process to survive

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by Professor Ahmed Ahmed at the Nuffield Department of Obstetrics & Gynaecology. This discovery could help clinicians identify and inhibit the process, giving them much better control of a person's cancer.

Cannabinoid biomedicine research programme launched

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.